

THE INFLUENCE OF SERUM LDL-CHOLESTEROL AND HDL-CHOLESTEROL ON SYSTOLIC BLOOD PRESSURE OF TYPE II DIABETIC PATIENTS WITH VARIOUS KIDNEYS FUNCTION NOT YET ON DIALYSIS

Hamid Nasri

Internist, Nephrologist, Associate Professor, Shahrekord University of Medical Sciences, Hajar Medical, Educational and Therapeutic Center, Hemodialysis section, Shahrekord, Iran.

Background: This study was undertaken to elucidate whether and how in patients with type II diabetes the serum lipid concentrations affect the blood pressure of the patients. **Methods:** Blood pressure (BP) of the patients were measured. For patients glycosylated hemoglobin (HbA1c) and serum lipids consisting of Triglycerides, cholesterol, High density lipoprotein were measured using standard methods. Serum LDL was calculated. **Results:** The present study included 122 patients (f=82, m=40). The mean patient's age was 63 (± 10) years. The mean length of the time they were diabetic was 7.4 (± 5.8) years (median: 6 years). The duration of hypertension was 3.2 (± 4.6) years (median: 96 months). The mean serum LDL-cholesterol was 112 (± 37) mg/dl (median: 112 mg/dl). The mean serum HDL-c was 47 (± 18) mg/dl (median: 44 mg/dl). In this study a significant inverse correlation of serum HDL with mean systolic BP. In this study also a significant positive correlation of serum LDL-c with mean systolic BP was found too. **Conclusion:** This study has important implications for the increased susceptibility to vascular disease associated with LDL-c in diabetic patients. Hence, higher plasma concentrations of LDL-c though within the normal range, could be an independent risk factor for developing hypertension or its aggravation. This study addressed the hypothesis the new therapeutic methods like statin groups may be identified to reduce LDL-C levels, which may prove to be useful in diabetic patients even in earlier onset of type II diabetes.

Key words: Hypertension, lipids, Diabetes Mellitus, glycosylated hemoglobin (HbA1c)

INTRODUCTION

Over the last decade there has been increasing interest in the clinical association between hypertension and diabetes.^{1,2} The prevalence of hypertension (HTN) is two times higher in diabetics than in non-diabetics. In type 1 diabetes mellitus (T1DM), the incidence of hypertension is similar to the incidence of nephropathy.³ In type 2 diabetes, hypertension is often present as part of the metabolic syndrome of insulin resistance also including central obesity and dyslipidemia, while in type 1 diabetes, hypertension may reflect the onset of diabetic nephropathy.⁴ Hypertension substantially increases the risk of both macrovascular and microvascular complications, including stroke, coronary artery disease, and peripheral vascular disease, retinopathy, nephropathy, and possibly neuropathy.^{4,5} Observational and clinical trial data have demonstrated that elevated systolic blood pressure (SBP) confers significantly higher risk of total and coronary heart disease mortality than elevated diastolic blood pressure (DBP) or combined systolic/diastolic hypertension, especially in those with diabetes mellitus.^{6,7} It was shown that atherogenic dyslipidemias were associated with the subsequent development of hypertension among healthy women⁶, even young, slender normotensive subjects with a positive history of hypertension may

show various alterations in lipid metabolism, suggesting a positive correlation between lipid metabolism and hypertension heredity as well.⁹ In essential HTN the disturbances of glucose and lipid metabolism may be related to both insulin resistance and compensatory hyperinsulinemia, and that insulin-resistant patients with essential hypertension may have more risk factors for arteriosclerotic complications than essential HTN.¹⁰ Indeed NIDDM and hypertension commonly co-exist and may be part of the insulin resistance or metabolic syndrome.¹¹ This syndrome describes a group of clinical and biochemical features which are strongly associated with accelerated atherosclerosis. These features include obesity, mixed dyslipidaemia (high triglycerides and low HDL [high density lipoprotein] cholesterol levels) and hyperinsulinaemia, as well as hypertension. The underlying association between hypertension and diabetes in this syndrome remains unknown, but it is possible that endothelial dysfunction as a result of both hypertension and diabetes could be an important factor in the high incidence of vascular disease in individuals with both conditions.¹² In this study we aimed to elucidate whether and how in patients with type II diabetes with various kidney function not yet on dialysis the serum lipid concentrations affect the blood pressure of the patients.

MATERIAL AND METHODS

This cross-sectional study was conducted on diabetic mellitus patients under treatment of either oral hypoglycemic agent and /+ biguanids or Insulin NPH and/+ regular injections with various dosages who admitted in the hospital for controlling the diabetes . Among study patients ones who had hypertension , took antihypertensive consisting of amlodine or diltiazem,beta blockers and/or thiazide diuretics at various doses. Exclusion criteria included the presence of any chronic or acute infections and use of lipid-lowering medications.

The study carried out from July to August of 2005in Hajar Medical Educational and Therapeutic Center of Shahrekord University of Iran. All patients signed the consent forms for participation in this study .

After admission all patients underwent history taking consisting the length of the time they were diabetic and/or hypertensive, their medicament for DM and HTN using a questionnaire. Patients also examined for blood pressure (BP) , body mass index measurement as well as heart , lower extrimities pulses and feet were examined too.

Blood Pressure Measurement

A trained physician measured all baseline BP using a random-zero manometer .Two BP and heart rate measurements were averaged to create the baseline BP and heart rate variables. Follow-up BP represents two measures on a single day after at least 30 minutes of rest. Hypertension was diagnosed according to WHO guidelines (13) and the seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (14).

Laboratory methods

Blood samples were collected after an overnight fast(12 hour overnight fasting) . Each blood samples were centrifuged within 15 min of venopuncture. For patients glycosilated hemoglobine(HbA1c) was mesearred by chromatography method using Hb-Gold of UK, the normal value in our laboratory is[less than or equal to]6.1%.Levels of serum creatinine(creat) , blood urea nitrogen(BUN) total protein were measured using standard methods.Serum lipids consisting of Triglycerids (Tg) , cholestrol (Chol) , High density lipoprotein(HDL-c) were measured using standard methods. Body mass index (BMI) calculated using the standard formula (weight in kilograms/height in square meters ; kg/m^2) .Serum LDL-cwas calculated by friedewald's formula (15). Creatinine clearance(CrCL) was evaluated from serum creatinine, age and body weigh (16).

Statistical analysis

Results are expressed as the mean \pm SD and median values. Statistical correlations were assessed using a partial correlation test.Comparison between female and male genders data was assessed using students't test .

All analyses were performed with the SPSS statistical package (version 11.00 for Windows; SPSS, Chicago).

Statistical significance was determined at a p-value <0.05.

RESULTS

The present study included 122 patients (f=82 ,m=40). Base line characteristics of patients are described in table one .The mean patient's age was 63 (± 10) years. The mean length of the time they were diabetic was 7.4 (± 5.8) years (median: 6 years). The duration of hypertension was 3.2 (± 4.6) years (median: 96 months). The mean systolic and diastolic BP were 138(± 23) mmHg and 83(± 12) mmHg respectively. The mean serum cholesterol was 198 (± 52) mg/dl (median: 192 mg/dl). The mean serum LDL-cholesterol was 112(± 37) mg/dl (median: 112 mg/dl) .The mean serum HDL-cholesterol was 47(± 18) mg/dl (median: 44 mg/dl) .In this study a significant inverse correlation of serum HDL with mean systolic BP ($r = - 0.177$ $p=0.050$;figure 1) (data adjusted for age and HgbA1c).In this study also a significant positive correlation of serum LDL-c with mean systolic BP ($r = 0.196$ $p=0.031$;figure 2) (data adjusted for age and HgbA1c) was found too.No significant correlation of serum triglyceride and cholesterol with duration of HTN or mean systolic BP were seen (P.N.S).More over no significant association of serum lipids with mean diastolic BP were seen too (P.N.S).




Figure 1: Significant inverse correlation of serum HDL-c with mean systolic blood pressure

Table 1: Minimum, Maximum, Mean \pm SD and Median values of patients' data also laboratory tests of the patients.

Number of patients=122	Minimum	Maximum	Mean \pm SD	Median
Age(years)	25	84	63 \pm 11	64
Duration of DM(years)	0.1	25	7.4 \pm 6.8	6
Duration of HTN(years)	0.00	25	3.2 \pm 4.5	0.80
BMI(kg/m ²)	30	53	25.5 \pm 4.5	25.3
Creinine Clearance (CICr) (cc/min)	10	110	64 \pm 24	64
HgbA1C %	3.9	13.3	7.6 \pm 1.9	7.6
Chol(mg/dl)	90	388	198 \pm 52	192
Tg(mg/dl)	37	580	183 \pm 102	155
LDL(mg/dl)	44	210	112 \pm 37	112
HDL(mg/dl)	19	128	47 \pm 18	44
Creatinine(mg/dl)	0.6	10	1.32 \pm 1.34	1




Figure 2: Significant positive correlation of serum LDL-c with mean systolic blood pressure.

DISCUSSION

In this study while there were not any significant association between serum lipids with mean diastolic blood pressure, a significant positive correlation of serum LDL-c with mean systolic blood pressure and a significant inverse correlation of serum HDL-c with mean systolic blood pressure were found. Patients with type 2 diabetes can have many lipid abnormalities, including hyperchylomicronemia; elevated levels of very low-density lipoprotein cholesterol (VLDL-c), low-density lipoprotein cholesterol (LDL-c), and triglycerides; and low levels of high-density lipoprotein cholesterol (HDL-c). These patients have a preponderance of abnormalities in the composition of LDL-c (smaller, denser particles), which increase atherogenicity even if the absolute concentration of LDL-C is not significantly increased.¹⁷ Both diabetes mellitus and hypertension alter lipid and lipoprotein metabolism and increase the risk of coronary artery

disease.¹⁸ It is well documented that loss of endothelial function not only is characteristic of diseases such as genetic or secondary hypertension, hypercholesterolemia, and atherosclerosis.¹⁹ Raised low-density lipoprotein cholesterol (LDL-c) may increase angiotensin II (Ang II) sensitivity. The present study in healthy, young subjects with isolated hypercholesterolemia shows an increased sensitivity to angiotensin II that partly can be restored by LDL-c-lowering therapy. These findings indicate that LDL-c levels directly influence Ang II sensitivity.²⁰ In young male subjects, responsiveness to Ang II is determined by the LDL-cholesterol serum level even in the normal range of LDL-cholesterol, thereby potentially contributing to the cardiovascular risk of LDL-cholesterol even within the so-called normal range.²¹ Our study has important implications for the increased susceptibility to vascular disease associated with LDL-c in diabetic patients. hence, higher plasma concentrations of LDL-c though within the normal range, could be an independent risk factor for developing hypertension or its aggravation. This study addressed the hypothesis the new therapeutic methods like statin groups may be identified to reduce LDL-C levels, which may prove to be useful in diabetic patients even in earlier onset of type II diabetes.

REFERENCES

1. Epstein M, Sowers JR. Diabetes mellitus and hypertension. *Hypertension* 1992; 19: 403-18.
2. Williams B. Insulin resistance; the shape of things to come. *Lancet* 1994; 344: 521-4.
3. Vasovic O, Zamaklar M, Lalic K, Milosevic D, Zikic L, Popovic L. The prevalence of hypertension and microalbuminuria in diabetes mellitus type 1 and type 2. *Srp.Arh. Celok Lek.* 2005 May-Jun; 133(5-6):229-32
4. Cushman WC. The clinical significance of systolic hypertension. *Am J Hypertens* 1998; 11: 182S-185S

5. Lackland DT, Egan BM. The dominant role of systolic hypertension as a vascular risk factor: Evidence from the southeastern United States. *Am J Med Sci* 1999;318: 365-8
6. Arauz-Pacheco C, Parrott MA, Paskin P. Treatment of hypertension in adults with diabetes. *Diabetes Care*. 2003 Jan;26 Suppl 1:S80-2
7. Tomlinson JW, Owen KR, Close CF. Treating hypertension in diabetic nephropathy. *Diabetic Care*. 2003 Jun;26(6):1802-5
8. Sesso H, Buring J, Chown M, Ridker P, Gaziano M. A Prospective Study of Plasma Lipid Levels and Hypertension in Women. *Arch Intern Med*. 2005;165:2420-7.
9. Lopez HF, Silva HB, Soares JA, Filho B, Consolim-Colombo FM, Giorgi DM, et al. Lipid Metabolism Alterations in Normotensive Subjects With Positive Family History of Hypertension. *Hypertension*. 1997;30:629.
10. Agata J, Miyazaki Y, Takada M, Murakami H, Masuda A, Miura T, et al. Association of insulin resistance and hyperinsulinemia with disturbed lipid metabolism in patients with essential hypertension. *Hypertens Res*. 1998 Mar;21(1):57-62.
11. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic vascular disease. *Diabetes Care* 1991; 14: 173-194.
12. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. *Diabetologia* 1989; 32: 219-226.
13. WHO Technical report series on Hypertension, Geneva 1996.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *JAMA* 2003;289:2560-71.
15. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of Low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem* 18: 799-502, 1972.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 16: 31-41, 1976.
17. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998;19:1434-503.
18. Nyarko A, Adubofour K, Ofei F, Kpodonu J, Owusu S. Serum lipid and lipoprotein levels in Ghanaians with diabetes mellitus and hypertension. *J Natl Med Assoc*. 1997 Mar;89(3):191-6.
19. Lüscher TF, Boulanger CM, Yang Z, Noll G, Dohi Y. Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. *Circulation*. 1993;87(suppl V):V-36-V-44.
20. Van der Linde NA, Sijbrands EJ, Boomsa F, Van den Meiracker AH. Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity. A Randomized Trial With Fluvastatin. *Hypertension* 2006 Apr 17.
21. John S, Delles C, Klingbeil AU, Jacobi J, Schlarch MP, Schmieder RF. Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. *J Hypertens* 1999 Dec;17(12 Pt 2):1933-9.

Address For Correspondence:

Dr Hamid Nasri, P.O. Box:88155-468-Shahrekord-Iran, Fax: (00)98 381 2243715 (hospital)

Mobile: (00)98 912 1439584

Email: hamidnasri@yahoo.com, hamidnasri@skums.ac.ir